Skip to main content

Smith + Nephew Plc Value Stock - Dividend - Research Selection

Smith and nephew

ISIN: GB0009223206 , WKN: 502816

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Baxter hires CFO from Smith & Nephew

2026-08-20
John Rogers, who has experience leading change at companies, is expected to help Baxter’s turnaround gain traction. He joins Baxter after the company sold two business units.

SNN Advances Surgical Robotics Through Imperial College Partnership

2026-08-19
Smith+Nephew's five-year Imperial College London partnership targets less invasive robotic surgery and could speed research into clinical use.

Disappointing Ortho Performance Continues To Hold Smith & Nephew Back (Downgrade)

2026-08-19
Smith & Nephew stock is downgraded to 'Hold' amid weak orthopedics, a guidance cut, and exec turnover. Here's what you need to know about SNN.

FTSE 100 Live: Blue-chips open higher as miners gain, UK inflation ticks up

2026-08-19
8.44am: Inflation may not move Bank of England dial Some thoughts on this morning's UK inflation numbers, which showed July's CPI up 2.9% from a year ago, increasing from 2.6% in June. Core CPI stayed put at 2.6%, while services CPI slowed to 3.4% from 3.6%. "What happened in July?...

Smith+Nephew Launches FLOW FLEXTEND COBLATION Wand for Hip Surgery

2026-08-18
SNN launches the FLOW FLEXTEND COBLATION Wand, offering adjustable-angle access and precise tissue removal in complex joint procedures.

Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics

2026-08-18
Marking a new approach to innovation in medical robotics, the new centre will bring advances from a leading surgical robotics research group to patients more quickly Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, and Imperial College London have launched a five-year partnership to deliver breakthrough research and innovation for robotic surgery for musculoskeletal conditions. The first-in-kind partnership will bring together a globally renowned academic laboratory with e

Smith+Nephew’s new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options

2026-08-17
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a breakthrough in RF resection technology for hip with its new FLOW FLEXTEND COBLATION Wand. Designed as an extension of its proprietary FLOW~IQ◊ technology with an adjustable-angle tip, the FLOW FLEXTEND Wand is designed to give surgeons enhanced joint access1* and precise tissue targeting3 for hard-to-reach hip, knee and shoulder anatomies. Determining the root cause of a patient’s hip pain can be very chal

Dividend Announcements: August 1-7, 2026

2026-08-16
Weekly dividend stock updates: 21 hikes, 1 cut, 1 special. See top picks BR, CSL & RMD—quality, safety and undervaluation.

Spectral AI, Inc. Q2 2026 Earnings Call Summary

2026-08-12
Moby summary of Spectral AI, Inc.'s Q2 2026 earnings call

Smith & Nephew SNATS Q2 Earnings Call Highlights

2026-08-09
Smith & Nephew SNATS (NYSE:SNN) reported second-quarter underlying revenue growth of 1.6%, below management’s expectations, as continued strength in Sports Medicine and ENT was offset by weakness in U.S. Orthopaedics and Advanced Wound Bioactives. Chief Executive Officer Deepak Nath said quarte